Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
146.1 ^USD	-0.46%		-1.20%	-6.76%

Apr. 26	Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment	MT
Apr. 25	Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	MT

Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

August 09, 2022 at 04:34 pm EDT

Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 20^th Annual Global Healthcare Conference on Wednesday, September 14^th, at the Sheraton New York Hotel in New York. Joaquin Duato, Chief Executive Officer, and Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005996/en/

Latest news about Johnson & Johnson

Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment	Apr. 26	MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	Apr. 25	MT
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	Apr. 24	DJ
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	Apr. 24	MT
J&J: EU green light for Carvykti in multiple myeloma	Apr. 22	CF
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	Apr. 22	MT
Contaminated cough syrup in Africa no longer available - WHO	Apr. 22	RE
WHO Likely to Issue Wider Warning About J&J Cough Syrup Contamination, Reuters Reports	Apr. 19	DJ
WHO says wider alert on contaminated J&J cough syrup 'likely'	Apr. 19	RE
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Medical device maker Intuitive beats estimates on strong demand for surgical robots	Apr. 18	RE
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	Apr. 18	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	Apr. 18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	Apr. 18	MT
Johnson & Johnson's Q1 Had 'Some Puts and Takes,' Morgan Stanley Says	Apr. 17	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	Apr. 17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	Apr. 17	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	Apr. 17	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	Apr. 17	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	Apr. 16	MT
US stocks see-saw as rising Treasury yields, Middle East tensions cap gains	Apr. 16	RE
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	Apr. 16	MT
Wall Street stocks mixed on higher Treasury yields, rate expectations	Apr. 16	RE
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	Apr. 16	MT

Chart Johnson & Johnson

Duration

Period

More charts

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).

Sector

Pharmaceuticals

Calendar

2024-05-14 - BofA Securities Health Care Conference

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST

More Strategies

Ratings for Johnson & Johnson

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

146.8 USD

Average target price

173.6 USD

Spread / Average Target

+18.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOHNSON & JOHNSON	-6.76%	354B
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B
PFIZER, INC.	-11.77%	143B

Other Pharmaceuticals

Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

EPS Revisions